Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

Cancer

Volumn 97, Issue 12, 2003, Pages 3010-3016

  Garcia Manero, Guillermo ^a   Talpaz, Moshe ^a   Giles, Francis J ^a   Cortes, Jorge ^a   Faderl, Stefan ^a   O'Brien, Susan ^a   Thomas, Deborah ^a   Verstovsek, Srdan ^a   Rios, Mary Beth ^a   Shan, Jianquin ^a   Ferrajoli, Alessandra ^a   Wierda, William ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; Cytogenetic response; Cytosine arabinoside; Polyethylene glycol interferon

Indexed keywords

ALPHA2B INTERFERON; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HOMOHARRINGTONINE; IMATINIB; MACROGOL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SCHERING 54031; SCHERING 54301; VINCRISTINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE PAIN; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DEPRESSION; DIARRHEA; DRUG FORMULATION; FATIGUE; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MOUTH ULCER; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SKIN DISEASE; SURVIVAL RATE; THROMBOCYTOPENIA; TREMOR; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONIC DISEASE; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON ALFA-2A; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 0037672700     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11424     Document Type: Article

References (21)

1. Kantarjian HM, O'Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999;17:284-292.
2. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-229.
3. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99:1527-1535.
4. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999;94:1517-1536.
5. Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry. 2000;39:10634-10640.
6. Talpaz M, O'Brien S, Rose E, et al. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 2001;98:1708-1713.
7. Hurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete problem list. Clin Cardiol. 1999;22:385-390.
8. National Cancer Institute. Common toxicity criteria, version 2.0. Available from URL: http://ctep.cancer.gov/reporting/ctc.html
9. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
10. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990;88:1-8.
11. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in chronic granulocytic leukemia. Blood. 1984;63:789-799.
12. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
13. Thomas D, Cortes J, Giles F, et al. Combination of hyperCVAD with imanitib mesylate (STI 571) for Philadelphia (Ph)-positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast phase (CML-LBP) [abstract]. Blood. 2001;98:803a.
14. Michallet M, Delain M, Maloisel F, et al. Phase III trial of PEG intron vs interferon alfa-2b for the initial treatment of chronic myelogenous leukemia [abstract]. Blood. 2001; 98: 348a.
15. Coiffier B, Haioun C, Delaby P, et al. Phase II study of PEG-intron in combination with chemotherapy for the treatment of first line patients with follicular lymphoma who need to be treated [abstract]. Blood. 2001;98:604a.
16. Gugliotta L, Russo D, Vainelli N, et al. PEG interferon alpha-2b (PEG-Intron) in essential thrombocythemia: Phase II study for determination of the minimum effective, safe and tolerated dose. Preliminary data [abstract]. Blood. 2001;98:629a.
17. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
18. Craddock C, Szydlo RM, Klein JP, et al. Estimating leukemiafree survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood. 2000;96:86-90.17. O'Brien S, Talpaz M, Cortes J. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic phase chronic myelogenous leukemia. Cancer. 2002;94:2024-2032.
19. Craddock C, Szydlo RM, Klein JP, et al. Estimating leukemiafree survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood. 2000;96:86-90.17. O'Brien S, Talpaz M, Cortes J. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic phase chronic myelogenous leukemia. Cancer. 2002;94:2024-2032.
20. Mollee P, Taylor K, Arthur C, et al. A Phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML) [abstract]. Blood. 2000;96:545a.
21. Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia. 1998;12:860-864.